Literature DB >> 30998197

[Epidemiological, clinico-biological, therapeutic and evolutionary aspects of β-thalassemia in Morocco].

Hanane Zahir1, Mohammed Chakour1, Hanane Mouhib1, Hicham Yahyaoui1, Mustapha Ait Ameur1.   

Abstract

OBJECTIVE: Thalassemias is the consequence of a synthesis imbalance between the α and β chains of hemoglobin. It's a hereditary haemolytic anemias, which presents a problem of public health because of their frequency and the difficulties of their care. The objective of this work is to study the epidemiological, clinico-biological, therapeutic and evolutionary profile of thalassemic patients in Morocco.
METHODS: We're reporting the results of a retrospective multicenter study on all cases of thalassemia taken at the hospitals: Avicenne military hospital in Marrakech, Mohammed VI hospital in Marrakech and the regional center for blood transfusion in Agadir.
RESULTS: During this period we collected 81 cases of thalassemias. The average age was 13 years (from 1 month to 60 years) with a sex ratio (M/F) of 0.8. The reason for consultation was anemia in 43% of cases. The electrophoresis of hemoglobin has shown a predominance of the β-thalassemia minor form. On the evolutionary level, iron overload and endocrine complications were the most frequent.
CONCLUSION: The development of a prevention program based mainly on health education, the reduction of consanguineous marriages and genetic counseling, are probably the main ways of combating the emergence of new thalassemic cases.

Entities:  

Keywords:  haemolytic anemia; hemoglobin electrophoresis; hemoglobinopathy; β-thalassemia

Mesh:

Year:  2019        PMID: 30998197     DOI: 10.1684/abc.2019.1433

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  1 in total

1.  The impact of the COVID-19 pandemic on the continuity of transfusion care for thallasemic patients: a case report.

Authors:  Sabah Bouhou; Mohammed Benajiba; Azlarab Masrar
Journal:  Pan Afr Med J       Date:  2021-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.